Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Probiotics & Respiratory & Gastrointestinal Illness - Nutraceuticals World

What are you searching for?

Sign in
Research

Probiotics & Respiratory & Gastrointestinal Illness

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Nutraceutical: Probiotics
Indication: Respiratory & Gastrointestinal Illness
Source: Clinical Nutrition, Oct. 14, 2013

Research: This study examined the effect of supplementation with probiotics on respiratory and gastrointestinal illness in healthy active men and women. The randomized, double-blind, placebo-controlled trial included 465 participants (241 males; age 35 ± 12 y (mean ± SD) and 224 females; age 36 ± 12 y), who were assigned to one of three groups: Group 1 – Bifidobacterium animalis subsp. lactis Bl-04 (Bl-04) 2.0 × 109 colony forming units (CFU) per day; Group 2 – Lactobacillus acidophilusNCFM and Bifidobacterium animalis subsp. lactis Bi-07 (NCFM & Bi-07) 5 × 109 CFU each per day); or Group 3 – placebo mixed in a drink.

Results: The risk of an upper respiratory illness episode was significantly lower in the Bl-04 group (hazard ratio 0.73; 95% confidence interval 0.55–0.95; P = 0.022) compared to placebo. There was no significant difference in illness risk between the NCFM & Bi-07 group (hazard ratio 0.81; 0.62–1.08; P = 0.15) and the placebo group.

There was a 0.7 and 0.9 month delay in the median time to an illness episode in the Bl-04 and NCFM & Bi-07 groups, respectively, compared to placebo (placebo 2.5 months; Bl-04 3.2 months; NCFM & Bi-07 3.4 months). There were insufficient GI illness episodes for analysis. The NCFM & Bi-07 group but not the Bl-04 group undertook significantly more physical activity (8.5%; 6.7%–10%; P < 0.003) than the placebo group.

Researchers concluded the probiotic Bl-04 appeared to be a useful nutritional supplement in reducing the risk of URTI in healthy physically-active adults.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics